Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIV201
- Development stage
- Unknown
- Lead developer
- BioVie
- Modality
- Peptides
- Administration
- Continuous Infusion
01
Overview
BIV201 is a continuous infusion formulation of terlipressin acetate being developed for the treatment of ascites due to liver cirrhosis. It is administered via a portable infusion pump, which delivers terlipressin slowly throughout the day rather than as a single bolus injection. This approach has shown to reduce the incidence of drug-related severe adverse events. BioVie has developed a novel liquid formulation of terlipressin that has demonstrated stability at room temperature for at least 12 months, which is considered an important advantage for treating ascites patients in home care settings.
- Other names
- continuous infusion terlipressin
02
Targets
AVPR1A (Arginine vasopressin receptor 1A)AVPR1B (Vasopressin V1b Receptor)AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on BIV201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIV201.